Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03170362 · ClinicalTrials.gov registry record · NA
PRIME Care (PRecision Medicine In MEntal Health Care)
A NA study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- NA
- Development phase
- 1,944
- Enrollment target
NCT03170362: Completed NA study, sponsored by VA Office of Research and Development.
NCT03170362 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 1,944 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (38% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03170362, a NA study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,944 participants
- Enrollment target
Study Summary
The focus of this application is on the impact of providing depressed Veterans and their providers with the results of pharmacogenetic (PGx) testing for psychotropic medications. The project focuses on whether and how patients and providers use genetic test results given to them at the time an antidepressant is to be initiated to treat Major Depressive Disorder (MDD) and whether use of the test results improves patient outcomes. MDD is one of the most common conditions associated with military service and combat exposure, increases suicide risk, and worsens the course of common medical conditions, making it a leading cause of functional impairment and mortality. Validation of a PGx test to personalize the treatment of MDD represents an important opportunity to improve the healthcare of Veterans.
Primary Outcome
The investigators will use the Patient Health Questionnaire 9 (PHQ9) as a self assessed marker of depression remission. The scale ranges from 0 to 27 with lower scores indicating less depression severity. Remission was defined as a score of 5 or less at the endpoint. the reported number of participants are those reaching that threshold of symptoms.
Interventions
- OTHER Pharmacogenetic Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,944 participants |
| Start Date | 2017-06-15 |
| Est. Completion | 2022-03-31 |
| Phase | NA |
What the finished NCT03170362 record still lists
NCT03170362 is an interventional study that assigns participants to a tested intervention. Its 1,944 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (38% higher).
The record links to 0 conditions, and to 1 intervention - of which Pharmacogenetic Test is the first listed.
NCT03170362 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03170362 about?
NCT03170362 is a clinical study titled "PRIME Care (PRecision Medicine In MEntal Health Care)". The focus of this application is on the impact of providing depressed Veterans and their providers with the results of pharmacogenetic (PGx) testing for psychotropic medications. The project focuses on whether and how patients and providers use genetic test results given to them at the time an antid...
What is the current status of trial NCT03170362?
This trial is currently completed. It is a NA study. The enrollment target is 1,944 participants. The study started on 2017-06-15. Estimated completion is 2022-03-31.
What interventions are being tested in trial NCT03170362?
The interventions under investigation include: Pharmacogenetic Test (OTHER).
Who is sponsoring clinical trial NCT03170362?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03170362's enrollment target sits among peer trials
1,944 55th of 2000 higher than 1,946 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04251052 · 1,956 participants · NA
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- NCT05233150 · 1,932 participants · NA
Child-Adult Relationship Enhancement in Primary Care (PriCARE) / Criando Niños Con CARIÑO (CARIÑO)
- NCT06058455 · 1,920 participants · NA
An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)
- NCT05174169 · 1,912 participants · Phase 2
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI